Bristol-Myers Squibb Co. (BMS) exited development of HIV therapies in a big way, selling its entire R&D pipeline of HIV assets to erstwhile competitor Viiv Healthcare Ltd., the joint venture established in 2009 by Glaxosmithkline plc and Pfizer Inc. to focus on HIV medicines.